The Ethylene Oxide Product Test of Sterility: Limitations and Interpretation of Results.


Journal

Biomedical instrumentation & technology
ISSN: 0899-8205
Titre abrégé: Biomed Instrum Technol
Pays: United States
ID NLM: 8905560

Informations de publication

Date de publication:
01 Mar 2021
Historique:
entrez: 21 6 2021
pubmed: 22 6 2021
medline: 24 6 2021
Statut: ppublish

Résumé

The ethylene oxide (EO) product test of sterility (ToS) can be conducted to comply with ANSI/AAMI/ISO 11135:2014 for the generation of data to demonstrate the appropriateness of the biological indicator (BI) that is used to develop and qualify the EO sterilization process. Clause D.8.6 of 11135 provides an option to perform a sublethal EO process, followed by conducting a product ToS, performing sterility testing of BIs from the process challenge device, and comparing the test results. Certain limitations for the EO product ToS should be considered when conducting studies that feature the use of this test, in order to support compliance with this requirement. Limitations for any sterility test include sample size, testing frequency, detection sensitivity, and/or the potential for false-positive/false-negative results, each of which must be recognized and well understood in order to support compliance with the standard. In addition, the experimental design of any study featuring the use of a sterility test should be carefully developed to ensure the generation of scientifically sound results and conclusions to support the study objective.

Identifiants

pubmed: 34153994
pii: 465985
doi: 10.2345/0899-8205-55.s3.45
pmc: PMC8655700
doi:

Substances chimiques

Ethylene Oxide JJH7GNN18P

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45-56

Informations de copyright

© Copyright AAMI 2021. Copying, networking, and distribution prohibited.

Références

Biomed Instrum Technol. 2016 Apr 2;50 Suppl 3:35-43
pubmed: 27100074
PDA J Pharm Sci Technol. 2007;61(1 Suppl TR1):2-51
pubmed: 17966927
J Parenter Sci Technol. 1984 Jul-Aug;38(4):141-7
pubmed: 6491857
J Bacteriol. 1933 Feb;25(2):101-21
pubmed: 16559606
Biomed Instrum Technol. 2009 Nov-Dec;43(6):489-97
pubmed: 20041540

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH